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The loss of dopamine neurons observed in Parkinson’s disease (PD) elicits severe motor
control deficits which are reduced by the use of dopamine agonists. However, recent
works have indicated that D3-preferential agonists such as pramipexole can induce
impulse control disorders (ICDs) such as food craving or compulsive eating. In the
present study, we performed an intermittent daily feeding experiment to assess the
effect of chronic treatment by pramipexole and VTA bilateral lesion on tolerance for
sucrose solution. The impact of such chronic treatment on spontaneous locomotion and
spatial memory was also examined. Changes in sucrose tolerance could indicate the
potential development of a change in food compulsion or addiction related to the action of
pramipexole. Neither the bilateral lesion of the VTA nor chronic treatment with pramipexole
altered the spontaneous locomotion or spatial memory in rats. Rats without pramipexole
treatment quickly developed a stable intake of sucrose solution in the 12 h access phase.
On the contrary, when under daily pramipexole treatment, rats developed a stronger and
ongoing escalation of their sucrose solution intakes. In addition, we noted that the change
in sucrose consumption was sustained by an increase of the expression of the Dopamine
D3 receptor in the core and the shell regions of the nucleus accumbens. The present
results may suggest that long-term stimulation of the Dopamine D3 receptor in animals
induces a strong increase in sucrose consumption, indicating an effect of this receptor on
certain pathological aspects of food eating.
Keywords: sucrose tolerance, ventral tegmenta area, Parkinson’s disease, dopamine agonist, pramipexole, food
compulsion
INTRODUCTION
The loss of dopamine (DA) producing neurons observed in
Parkinson’s disease (PD) elicits severe motor control deficits
including rest tremor, bradykinesia, and rigidity. While dopamine
replacement therapy (DRT) reduces motor symptoms, a grow-
ing number of studies have shown that the use of DRT, in
particular dopamine agonists, induces impulse control disorder
(ICD) such as dopamine dysregulation syndrome, hypersexual-
ity, pathological gambling, compulsive shopping, and disturbance
of eating behavior (Courty et al., 1997; Gallagher et al., 2007;
Voon and Fox, 2007; Merims and Giladi, 2008; Weintraub et al.,
2010). Clinical studies have shown that PD patients occasionally
develop food craving or compulsive eating disorder (Nirenberg
and Waters, 2006; Miwa and Kondo, 2008; Rieu et al., 2011).
Such abnormal behavior generally induces a significant, unde-
sired weight gain that can disturb the PD patient’s quality of
life.
Progressive loss of dopaminergic neurons leads to the dener-
vation of both the nigro-striatal pathway (around 80%) from the
substantia nigra (SN) and the mesocorticolimbic system (around
40%) from the ventral tegmental area (VTA) (German et al.,
1989). Although the loss of dopaminergic neurons in the SN is
directly linked to the motor and apathy symptoms observed in
PD patients and animal models (Dagher and Robbins, 2009; Drui
et al., 2013), the relation between the lesion of the dopaminer-
gic brain region and ICD remains unclear. Although the lesion
of the VTA in Parkinsonian patients is rather limited, the loss
of dopaminergic neurons in this brain region could account, at
least partially, for the development of ICD in PD patients under
DRT. Indeed, the main dopaminergic afferent projections com-
ing from the VTA are directed to the nucleus accumbens (Acb).
The dopamine arising from these afferent projections acts on
the Dopamine D2 and D3 receptors in the Acb. This nucleus
plays a key role in the regulation of the mesocorticolimbic sys-
tem (Robinson and Berridge, 2001) due to its place in the brain’s
reward circuit.
Dopamine agonists, particularly pramipexole (PPX), induces
conditioned place preference in normal animals as well as those
with 6-OHDA lesions of the striatum or SN (Papp, 1988; Riddle
et al., 2012; Zengin-Toktas et al., 2013). Interestingly, it was
observed that sham-operated animals need a higher dose of
PPX to induce conditioned place preference compared to rats
with dopaminergic lesions in the striatum, pointing to poten-
tially higher sensitivity to the reward properties of PPX in rats
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with lesions (Riddle et al., 2012). In addition, recent works have
found that rats with lesions of the posterior region of the VTA
develop a conditioned place preference induced by D2 and D3
agonists (Ouachikh et al., 2013), while lesion of the anterior
region of the VTA disrupts the ability of rats to learn condi-
tioned place preference (Ouachikh et al., 2014). Although the
conditioned place preference paradigm appears to be limited
to the study of motivational aspects linked to ICD, such data
could indicate possible interaction between dopamine agonist
treatment and lesion of the VTA region, potentially leading to a
change in motivated behaviors. In addition, recent clinical stud-
ies from Thobois et al. (2010, 2013) have shown that non-motor
symptoms (apathy, depression, and anxiety) was more expressed
in patients with enhanced denervation of mesocorticolimbic
pathway.
If VTA denervation contributes to CPP learning in rodents
and to apathy, depression, and anxiety in PD patients, it is
possible that it could also participate in certain aspects of impul-
sive/compulsive disorders. To address this question, we chose
in the present work to investigate the effect of VTA lesion and
dopamine agonist treatment in a model of compulsive food dis-
order, i.e., intermittent daily feeding. Intermittent daily feeding
is a well-described behavioral animal model of food addiction
or binge eating in which rats develop tolerance to sucrose solu-
tion by successive day-to-day access as well as signs of with-
drawal when access to sucrose is removed (Avena et al., 2008a,b;
Avena, 2010). Using this behavioral approach, we investigated
the effect of the lesion of the VTA region and chronic PPX
administration on sucrose solution tolerance, which preferen-
tially activates the D3 receptor at low doses (Collins et al., 2005).
Interestingly, an increase of D3 mRNA expression in the neu-
rons of the direct striatonigral pathway was observed in rats
with 6-OHDA lesion under chronic administration of L-Dopa
(Bordet et al., 2000). Furthermore, this receptor is implicated
in certain aspects of drug dependence such as drug seeking and
relapse (Le Foll et al., 2005). Blockade of the D3 receptor by
a selective antagonist has been reported to transiently alleviate
craving to nicotine in smoking addicts (Mugani et al., 2013)
and to disrupt morphine triggered cocaine induced CPP in rats
(Rice et al., 2013).
The aim of the present study was to assess the effect of
pramipexole and bilateral VTA lesions in rats on tolerance for
sucrose solution using a model of daily intermittent sucrose
access, which is considered to mimic aspects of compulsive food
eating in humans. In addition, we also explored the effect of such
chronic treatment on motor, cognitive, and anxiety-like traits. In
addition, change in D3 expression in the Acb was explored.
MATERIALS AND METHODS
SUBJECTS
Forty-five male Sprague Dawley rats (Charles River, Les Oncins,
France) weighing 200–225 g were housed individually. Animals
had access ad libitum to food and water before the behavioral
studies were started. All the experiments were carried out in con-
formity with the European Committee Council Directive of 24
November 1986 (86/609/EEC) and were approved by the local
ethical committee (CEMAAuvergne).
BILATERAL 6-OHDA LESION AND PRAMIPEXOLE TREATMENT
Animals were anesthetized by an i.p. injection of mixture
of ketamine (60mg/Kg) and xylazine (20mg/Kg) and treated
with desipramine (25mg/Kg, i.p., Sigma France) 30min before
6-OHDA injection. Bilateral lesions of the VTA were performed
by micro injection of 6-OHDA (2µg/µL, dissolved in NaCl 0.9%
with 0.01% of ascorbic acid solution, Sigma France) at the follow-
ing coordinate: AP: –5.2mm; Lat: ± 0.8mm; DV: –7.6mm from
the bregma at a speed of 0.125µL/min for a total of 1µl injected
on each side. The syringe was left in position for at least 10min
to reduce diffusion along the needle tract. Sham-operated ani-
mals received the same procedure with the infusion of the vehicle
(NaCl 0.9% with 0.01% of ascorbic acid solution, Sigma France).
Animals had a 2-week rest period to regain normal home caged
behaviors and to stabilize the 6-OHDA lesion.
Two groups of rats (sham and 6-OHDA lesioned rats) were
treated daily with an s.c. injection of pramipexole (PPX, Sigma
France) at a dose of 0.1mg/kg/day (dissolved in 0.9% NaCl). PPX
was administered every morning at 7 a.m. by subcutaneous injec-
tion from the 17th experimental day (Figure 1) to the end of
the experiment (day 49, so rats were treated for 32 days). Two
other control groups (sham and 6-OHDA lesioned rats) were s.c.
injected daily with 0.9% NaCl solution. Lesioned and sham ani-
mals treated with PPX are referred to as L-PPX (n = 12) and
Sh-PPX (n = 10), respectively. The control groups are referred to
as L (n = 12) and Sh (n = 11) for the lesioned and sham groups,
respectively. The treated animals received an injection once a day
at the same time (7 a.m.) and at least 2 h before behavioral tasks
took place.
BEHAVIORAL TESTING
After a recovery period, all the animals completed the following
sequence of behavioral tests (Figure 1). Animals were evaluated
in open field box and alternation in a Y maze in order to estimate
spontaneous locomotor activity and spatial memory before and
after 1 week of PPX treatment, respectively. The anxiety level of
animals was measured the day before and 2 days after the last day
of access to the 10% sucrose solution.
Y maze
Alternation in the Y maze made of gray plastic was performed
under soft light (30–35 lux). It consisted of three identical
branches (45 cm long, 13 cm wide, and 20 cm high) which
diverged at an angle of 120◦ from the central point. Animals
were placed in the start branch and freely explored the maze for
5min. The orders of the visits were noted by the observer. The
maze was cleaned with hot water and ethanol between each run.
Alternation was determined from successive entries (four paws
inside the branch) of the three branches by overlapping triplet sets
in which three different branches were entered (Taghzouti et al.,
1986; Pioli et al., 2008). The alternation score was obtained by
dividing the number of alternations by the number of alternation
opportunities (the total branch entries minus 2).
Open field
Spontaneous motor activity was measured in an open field
box (75 cm long, 75 cm wide, and 45 cm high) placed under
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FIGURE 1 | Time schedule of behavioral experiments. After a period of
acclimation to animal house, rats received 6-OHDA or vehicle solution
injection in the VTA. After the recovery period of 2 weeks, all animals were
evaluated for spontaneous locomotion and spontaneous alternation in Y
maze on 2 days. After the first evaluation, chronic PPX treatment starts with
daily administration of 0.1mg/kg/day of PPX by s.c. injection and last until the
end of the experiment (light gray box). A second evaluation of spontaneous
locomotion and spontaneous alternation in Y maze was performed after 1
week of PPX treatment. The anxiety level of animal was measured using
elevated plus maze, the day before and 2 days after the last day of the 10%
sucrose solution access. Intermittent daily feeding was assessed during 19
consecutive days.
a camera used to record each trial under soft lighting (30–
35 lux). Animals were placed in the center of the box and
were allowed to move freely during 15min. All sessions were
video-recorded and analyzed with EthoVision XT 8.5 (Noldus,
Netherlands). The open field arena was then cut in 16 squares
of identical size for analysis. The mean distance run (in cm) and
number of squares crossed and the numbers of rearings were
analyzed.
Elevated plus maze
Anxiety behavior was assessed using an elevated plus maze (50 cm
long, 10 cm wide, 10 cm high for the protected arms, 52 cm from
the ground) under soft illumination (30–35 lux) and a camera was
used to record all the trials. Rats were placed in the center of the
device and were free to move for 5min. The time spent in open
arm ratio (OTR) was calculated by dividing the times spent in the
open arm by the time spent in the open and closed arms. OTRwas
used as the measure of anxiety as well as the number of entries
in the non-protected arms in comparison to the protected one.
The experiment was analyzed using EthoVision XT 8.5 (Noldus,
Netherlands).
Intermittent daily feeding
All experimental groups were placed under daily alternation
for 19 days. During this period, animals received a drink-
ing bottle containing a 10% sucrose solution at the start
of the dark phase (12 h). The present protocol was adapted
from the studies of Avena et al. (2008a,b) to our animal
house condition. The bottles containing the 10% sucrose
solution was given to rats immediately at the start of the
dark period (7 p.m.) and removed at the start of the light
phase (7 a.m.). Animals had access to tap water only dur-
ing the light phase. The amount of sucrose solution (in g.)
was noted by weighing the bottle before and after the
dark period. Food was accessible ad libitum throughout the
experiment.
Detection of tyrosine hydroxylase and Dopamine D3 receptor
expression
After the completion of the behavioral evaluations, rats were
killed by chloral hydrate injection. The brains of the animals were
collected and post-fixed for 24 h in PFA 4%, before being pro-
cessed for paraffin embedded sections. Paraffin blocs were then
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serially cut into 7µm thick sections (first slice chosen randomly)
and mounted on glass slides.
Detection of tyrosine hydroxylase (TH) was used to determine
the extent of the 6-OHDA lesion. Paraffin was removed by suc-
cessive baths of xylene, ethanol and bathing in hot citrate buffer
for 25min. After cooling at room temperature, the slides were
rinsed in tris-phosphate buffer 0.1M (TBS 0.1 M) and endo-
geneous peroxydases were quenched with TBS 0.1M with 5%
H2O2 for 30min. Sections were then incubated with anti-TH
antibody (1/5000, rabbit, AB152 Milipore USA) diluted in DAKO
REAL antibody diluents overnight at room temperature. The next
day, the presence of the epitope was revealed using the DAKO
LSAB and HRP system (DAKO Real, DAKO France). The reac-
tion allowed localizing the expression of TH by brown labeling
on the slides. In order to reduce the differences in background
labeling between all the slides, all the slides from the experiments
were processed at the same time for TH immunohistochemistry
under the same laboratory conditions. TH-positive neurons were
counted using ImageJ software on 12 slices from the anterior to
posterior axis of the brain. The numbers of positive cells in both
VTA and SN were estimated with the method described by Paillé
et al. (2007).
Slices containing the accumbens and striatum at the level
around +2.16mm from Bregma were processed for the detec-
tion of Dopamine D3 receptor expression. After pretreatment, the
slices were incubated at room temperature with TBS solution con-
taining 3% normal goat serum (NGS, Jackson ImmunoResearch
USA) for 1 h. After rinsing, the slices were incubated overnight
at 4◦C with a solution of TBS containing 1% NGS and anti-
dopamine D3 receptor antibody (1/200, rabbit polyclonal, sc-
9114, Santa Cruz USA). The next day, the slides were rinsed
using TBS and incubated with secondary antibody (goat anti rab-
bit alexa 488, Jackson ImmunoResearch USA) for 1 h at room
temperature. The slides were rinsed andmounted using Dako flu-
orescent mounting medium and kept in the dark at 4◦C before
analysis. In order to reduce the differences in background label-
ing between all the slides, all the slides from the experiments
were processed at the same time for D3R immunohistochemistry
under the same laboratory conditions. Observation of the fluores-
cent labeling was done using a Zeiss microscope and AxioVision
software. The number of positive cells was counted in 100µm²
square windows, positioned at the same place using a brain atlas.
In the Acb, one window was used for the core region and one win-
dow for the shell region. The numbers of positive cells was noted
as the mean number of cells per 100µm².
DATA ANALYSIS
All behavioral data were expressed as mean ± S.E.M. for each
experimental group and analyzed using a Two-Way repeated-
measures analysis of variance (ANOVA) with lesion (two lev-
els, lesioned and sham) and treatment (two levels, PPX or
saline) as within subject factors. When appropriate, data were
compared using the Tukey–Kramer post-hoc test for multiple
comparisons.
For sucrose consumption, the intake of sucrose was also
expressed using the area under curves (A.U.C.). The A.U.C. was
obtained by summing the squares under the curves for each group
using the trapezoidal rule as followed: [(VTtime X – VTtime 0)
(time X – time X-1)]. The A.U.C. values, the mean number of
TH positive cells and the mean number of D3 positive cells were
analyzed by a One-Way ANOVA with the experimental groups
(four levels, L or L-PPX or Sh or Sh-PPX) as the factor and, when
appropriate, data were compared using Tukey–Kramer post-hoc
tests for multiple comparisons. Statistical analysis was performed
with SAS 9.1 software (SAS institute Inc., USA).
RESULTS
BILATERAL PARTIAL LESIONS OF THE VTA
The effect of the bilateral micro-injection of 6-OHDA revealed by
TH-immunoreactivity indicated a discrete pattern of dopamine
denervation centered on the VTA. One-Way ANOVA showed a
significant effect of the groups for the VTA region only [F(3, 43) =
57.66; p < 0.0001]. In this region, the mean number of TH posi-
tive cells was significantly (p < 0.05) lower in L and L-PPX groups
compared to Sh and Sh-PPX groups (Figure 2A). A decrease of
36% and 33% of TH-positive cell density was observed in L and
L-PPX groups respectively compared to sham rats. Lesion of the
VTA appeared to be restricted to the medial part of the VTA in L
and L-PPX rats (Figure 2B), a region known to mainly project to
the accumbens nucleus. On the contrary, the decrease in the SN
remained very low (less than 2%) and no significant differences
were observed between groups.
FIGURE 2 | Partial bilateral lesion of VTA by 6-OHDA micro-injection.
The injection of 6-OHDA produced a decrease in the number of TH-positive
cells within the VTA of lesioned rats (A). The dark gray bar represented the
number of positive cells counted in the SN, while light gray bar represented
the number of positive cells counted in the VTA region. Microphotographs
illustrated the dopamine denervation following 6-OHDA injection in Sh
(B-1), Sh-PPX (B-2), L (B-3), and L-PPX (B-4). The dash line square
represents the region where lesion is the most representative. Black scales
bars represent 100µm. Microphotographs were taken around −5.28mm
from the Bregma.
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BEHAVIORAL RESULTS
Effect of the daily PPX treatment
Spontaneous locomotor activity in the open field. The Two-
Way ANOVA with repeated measures did not show a significant
effect of factors on the mean distance run in the open field
arena (Figure 3A) or the amount of rearing (Figure 3B). Overall,
the PPX daily administration had no impact on the locomotor
activity of rats, whether they were lesioned or not.
FIGURE 3 | Daily administration of pramipexole (PPX) has no effect on
spontaneous locomotors activity and spontaneous alternation Y
maze. Spontaneous locomotor activity (A) and rearing (B) were not
affected by the VTA lesion (white bars) or by 1 week of daily administration
of PPX (gray bars) whatever the experimental group considered. The
alternation score measure in Y maze (C) was not modified by neither the
lesion (white bars) nor 1 week of daily PPX administration (gray bars). Sh,
Sham animals; Sh-PPX, sham animals with daily pramipexole treatment
(0.1mg/kg/day); L, VTA lesioned rats; L-PPX, VTA lesioned rats with daily
pramipexole treatment (0.1mg/kg/day).
Spontaneous alternation in the Y maze. The Two-Way ANOVA
with repeated measures indicated significant interaction between
repetition and treatment [F(1, 43) = 8.34; p < 0.05] without sig-
nificant difference in the post-hoc tests. We noted that the alter-
nation score in Sh and L rats appeared to decrease slightly 1
week after daily PPX treatment (Figure 3C), whereas its increased
slightly in L-PPX rats, although these differences were not
significant.
Intermittent daily feeding
The daily intake of a 10% sucrose solution for the 12 h of the
dark period escalated over the days, irrespective of the exper-
imental group considered (Figure 4A). The Two-Way ANOVA
for repeated measures indicated a significant effect of treat-
ment [F(1, 43) = 8.56; p < 0.05], a significant effect of repetition
[F(18, 774) = 26.8; p < 0.0001] and an interaction between repeti-
tion and treatment [F(18, 774) = 7.48; p < 0.0001]. An additional
analysis using a One-Way ANOVA with day as factor for each
group indicated an effect only in L-PPX and Sh-PPX [respectively
F(18, 246) = 9.15; p < 0.0001 and F(18, 208) = 7.91; p < 0.0001].
The day-to-day sucrose intake slowly escalated from the first to
the tenth day for all experimental groups. In the L group, although
rats drank less sucrose solution than the other groups (no signif-
icant difference), their intake escalated slowly. On the 14th day,
a clear distinction appeared between groups. Since the sucrose
solution intake remained stable for the rats receiving saline injec-
tions, those treated with pramipexole continued to increase their
sucrose intake slowly. The sucrose consumption of rats treated
with pramipexole was significantly (p < 0.05) higher compared
to the saline treated groups on the 18th and 19th days, indicated
by the Tukey post-hoc test.
Interestingly, in the L-PPX and Sh-PPX groups, the shapes of
the sucrose intake escalation curves were similar with a continu-
ous increase of sweet solution intake. From the 11th day to the
13th day, the sweet solution intake for the L-PPX group con-
tinued to increase, while it remained mostly constant for the
other groups. On day 14 to day 19, the volume of 10% solution
consumed by L-PPX rats was significantly (p < 0.05) higher com-
pared to L rats. For the Sh-PPX group, sucrose solution intake was
significantly (p < 0.05) higher compared to L rats, but was never
significantly different from Sh rats. In addition, the A.U.C. analy-
sis showed a significant group effect [F(3, 43) = 2.80; p = 0.05] in
a One-Way ANOVA with group. Post-hoc tests indicated that the
A.U.C. was significantly (p = 0.05) higher for the L-PPX group
compared to the L (Figures 4B,C).
Change in anxiety after removing sucrose access
Change in OTR. The Two-Way ANOVA for repeated measures
indicated an effect of repetition [F(1, 43) = 28.83; p < 0.0001], of
treatment [F(1, 43) = 17.43; p < 0.0001] and a significant inter-
action between these two factors [F(3, 43) = 20.03; p < 0.0001]
on the OTR ratio measure before and after access to sucrose.
Before the initiation of intermittent access to the sucrose solu-
tion, the OTR ratio was significantly (p < 0.001) lower in the
L-PPX groups compared to all the other experimental groups
(Figure 5A). In addition, we also noted that this ratio in Sh-PPX
rats was significantly (p < 0.05) lower compared to that of Sh
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FIGURE 4 | Sucrose solution consumption during intermittent daily
feeding. Intake of the 10% sucrose solution escalates over the 19 days (A)
whatever the group considered. Since the consumption of L rats (white
triangle and black dash line) and Sh rats (white circles and gray dash line)
escalated slowly and stabilized, the intake of Sh-PPX (gray circles and gray
bold line) and L-PPX (black triangle and black bold line) rats increased quickly
over days. The • represent significant (p < 0.05) and •• significant (p < 0.001)
difference between L and L-PPX rats, the # indicated that Sh-PPx rats were
significant (p < 0.05) different from L ones. The black number indicates
significant (p < 0.05) difference with previous days for L-PPX rats, the gray
one is for Sh-PPX group. For example the sucrose intake of L-PPX rats was
significantly (p < 0.05) higher in day 14 compared to day 1, 2, 3, and 5. The
area under curves (A.U.C.) analysis (B) showed that L-PPX group was
significantly (∗p < 0.05) higher compared to L rats. The intake of 10%
sucrose solution of each animals and the mean of each group was
represented to observe the potential distribution of rats (C). L-PPX rats: black
triangles, L Rats: white triangles, Sh-PPX rats: gray circles and Sh rats: white
circles. Sh: Sham animals, Sh-PPX: sham animals with daily pramipexole
treatment (0.1mg/kg/day), L: VTA lesioned rats, L-PPX: VTA lesioned rats
with daily pramipexole treatment (0.1mg/kg/day).
rats. When the OTR was evaluated again 2 days after removing
access to the sucrose solution, we noted a significant (p < 0.05)
decrease in this ratio in all the animal groups compared to the
value before the period of access to sucrose. Nevertheless, we did
not observe significant differences in this ratio between the exper-
imental groups when evaluated after the withdrawal of access to
sucrose.
Number of entries in the open arms. The frequency of entry
into the open arms was also analyzed as an index of anxiety. The
Two-Way ANOVA for repeated measures indicated a significant
effect of the treatment factor [F(1, 43) = 4.28; p < 0.05] and of
repetition [F(1, 43) = 70.64; p < 0.0001]. Tukey–Kramer post-hoc
test indicated that saline treated animals were significantly (p <
0.05) different from the PPX treated ones (Figure 5B). The
decrease of the frequency of entrance between before and after
sucrose access was around 58% in Sh animals, 55% in Sh-PPX
animals, 50% in L animals, and 64% in L-PPX animals, but no
significant differences were observed between groups.
CHANGE OF DOPAMINE D3 RECEPTOR EXPRESSION IN THE
ACCUMBENS NUCLEUS REGION
Analysis of D3R immunoreactivity in the core (Figures 6A,C) and
shell (Figures 6B,D) regions of the Acb by a One-Way ANOVA
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FIGURE 5 | Effect of sucrose access removal on anxiety measured by
elevated plus maze. (A) Time spent in open arm ratio (OTR) for each
experimental groups before intermittent daily access (white bars) and after
2 days of removing access to sucrose solution (gray bars). OTR was
significantly lower in L-PPX compared to all other groups before access to
sucrose (†p < 0.001). OTR was also significantly lower in Sh-PPX compared
to Sh one (∗p < 0.05). When access to sucrose was removed to animals,
we noted a significant decrease of the OTR in all experimental groups
compared to value before access to sucrose solution (p < 0.05). (B) The
number of entries in open arms was significantly decreased (∗∗∗p < 0.0001)
when compared before having access to 10% sucrose solution period
(white bars) to after removal access period (gray bars). Sh, Sham animals;
Sh-PPX, sham animals with daily pramipexole treatment (0.1mg/kg/day); L,
VTA lesioned rats; L-PPX, VTA lesioned rats with daily pramipexole
treatment (0.1mg/kg/day).
indicated a significant effect of the experimental group for these
two brain regions [core: F(3, 24) = 8.17; p < 0.05; shell: F(3, 24) =
4.77; p < 0.05]. Post-hoc tests indicated that the number of pos-
itive cells in the core region was significantly (p < 0.05) higher
in the L-PPX group compared to the Sh and Sh-PPX groups. In
addition, in the shell region, the D3R positive cell population was
significantly (p < 0.05) higher in the L-PPX rats compared to the
Sh group.
DISCUSSION
In this study, we investigated the respective roles of lesion of the
VTA and chronic treatment with PPX (32 days) on intermittent
daily access to sucrose solution in rats. The main findings are (i)
VTA lesion does not change the amount of sweet solution con-
sumed; (ii) PPX chronic treatment induced in sham and lesioned
animals a strong increase of tolerance to sucrose solution, sus-
tained by a strong increase of the amount of sucrose solution
drank; (iii) an increase of the dopamine 3 receptor in the shell and
the core regions of the nucleus accumbens in animals receiving
PPX, with a higher expression in lesioned rats compared to sham;
(iv) and finally an increase of anxiety behavior in each group of
animals after withdrawal of sucrose access.
When intermittent access to the sweet solution was given to
sham animals with saline treatment, we observed an escalation of
intake followed by a stable phase. This result is in agreement with
previous studies of Avena et al. (2008a,b) showing that animals
developed a tolerance for sucrose solution intake when given by
intermittent access, followed by a stable phase. Thus, intermittent
daily feeding has been described as a model of binge eating in ani-
mals since it shares common features with substance dependence
such as tolerance and signs of withdrawal (Avena, 2010).
Lesion of the VTA did not change the time-course of sucrose
intake. This result is in agreement with studies showing that
interference with nucleus accumbens dopamine transmission by
depletions or antagonisms has little or no effect on food intake
(Salamone and Correa, 2012, 2013) and that 6-OHDA lesion of
the VTA has no effect on consumption of sucrose in the 2 h
test period with a two bottle test (Shimura et al., 2002). Indeed,
although it is known that modification of dopaminergic inner-
vations from midbrain VTA to forebrain structures, including
the nucleus accumbens in the ventral striatum, decreases effort-
related behavior for food, the acquisition of visual-to-sucrose
Pavlovian associative learning and development of instrumen-
tal goal-directed behavior (Parkinson et al., 2002; Nicola et al.,
2005), such manipulation of dopamine leaves the motivation to
approach and consume food intact (Salamone and Correa, 2009).
Such preservation of motivation could account for the contin-
ued sucrose intake escalation observed in lesioned rats. In the
context of the intermittent daily feeding experiment, animals did
not need to make an association between cues (odor or taste)
and sucrose delivery, so they did not need dopamine to trig-
ger associative processes such as “incentive salience attribution”
(Berridge and Robinson, 1998). Accordingly, in intermittent daily
feeding, it can be assumed that dopamine from the VTA may act
only on the initial phase of approach and motivation toward the
sucrose solution, while continued escalation could imply other
neurotransmitters such as opioids or acetylcholine (Avena et al.,
2008a,b) and the action of other brain regions such as the amyg-
dala or prefrontal cortex (Diaz et al., 1995; Hitchcott et al., 1997).
An alternative hypothesis is that moderate lesion of VTA, as per-
formed in the present study, leaves compensatory mechanisms
intact enough to elicit motivation toward the sucrose solution.
The present data are the first to have been obtained from
investigation into the effect of chronic treatment with PPX on
day-to-day sucrose intake in animals with lesion of dopamin-
ergic brain system. In both lesioned and sham rats, chronic
PPX induced a strong increase of the amount of sucrose solu-
tion drank and its ongoing escalation. This result showed that
PPX elicited a marked shift in animal tolerance for sucrose. The
present results were in agreement with the ones from the study
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FIGURE 6 | Changes in Dopamine D3 receptor expression following
PPX treatment and intermittent access to sucrose solution. In the
core region of the accumbens nucleus (A,C), the number of D3 positive
cells was significantly (∗p < 0.05) higher in L-PPX rats compared to Sh
and Sh-PPX ones. Number of D3 positive cells was also significantly
(∗p < 0.05) higher in the shell region of the accumbens nucleus (B,D) of
the L-PPX rats compared to Sh ones. Microphotographes are high
magnification (×40) of the core (C) or the shell (D) regions taken at
around 2mm from Bregma. White scales bars represent 200µm. Sh,
Sham animals; Sh-PPX, sham animals with daily pramipexole treatment
(0.1mg/kg/day); L, VTA lesioned rats; L-PPX, VTA lesioned rats with daily
pramipexole treatment (0.1mg/kg/day).
of Willner et al. (1994). They showed that chronic PPX treatment
restored 1% sucrose solution intake in mild stressed rats as well
as non-stressed rats. In the case of stressed animals, chronic PPX
reversed the stress induced anhedonia, but also induced increase
of sucrose intake in normal rats. The role of dopamine in food
eating behavior remains controversial in humans and animals,
there is strong evidence to suggest that dopamine may partici-
pate in food seeking. Indeed, the Dopamine D3 receptor agonist
participates in reinstating food seeking at larger doses and poten-
tiates food primed response at low doses (Duarte et al., 2003).
In humans, PPX induces weight gain and also restores hunger
in PD patients (Kumuru et al., 2006). Furthermore, PD patients
under PPX can develop compulsive food eating traits as well as
gain weight. Interestingly, when PPX is lowered or discontinued,
these symptoms disappear or are reduced (Nirenberg andWaters,
2006). Finally, it has been shown that in overweight and obese
subjects, Dopamine D3 receptor antagonists decrease attentional
bias toward food cues in low-restrained eaters (Nathan et al.,
2012). Thus, the main result of the present work indicate that
PPX acts on both lesioned and sham animals by inducing higher
tolerance for sweet solutions, pointing to a potential role of D3
receptor stimulation in certain aspects of food-related addiction
and compulsion. Such a shift in sucrose intake also seemed to be
sustained by molecular modifications in the Acb in the present
study.
We showed that D3 receptor expression was higher in ani-
mals under chronic treatment compared to those under saline
treatment. In addition, we also noted that the number of cells
expressing the D3 receptor was significantly higher in the core of
the Acb of L-PPX rats compared to Sh-PPX ones. The D3 receptor
subtype is mainly expressed in the mesocorticolimbic dopamine
pathway (Sokoloff et al., 2001). Recent studies have pointed out
that the D3 receptor, which is mostly expressed in the Acb, could
play an important role in reinforcement and reward (Heidbreder
et al., 2005; Chen et al., 2006). Due to its particular pattern of
expression, the D3 receptor has drawn attention due to its poten-
tial role in the dysregulation of motivated behaviors in humans
(Gyertyán and Gál, 2003; Everitt et al., 2008; Besson et al., 2010)
and animals (Engelm et al., 2012). It has been proposed that
food anticipation, consumption, and unconditioned consumma-
tory behavior (i.e., eating) activate DA release in their terminal
fields, especially in the Acb and prefrontal cortex (Phillips et al.,
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1991; Bassareo and Di Chiara, 1997). Such release also seems to be
dependent on the reinforcing attraction of available food and on
the motivational state of the animal (Wilson et al., 1995; Martel
and Fantino, 1996). One possible explanation for our results
could be that chronic PPX administration might have amplified
the signal associated with the primary reinforcing effect of sucrose
presentation in the Acb which contains the D3 receptor at high
density, facilitating food-seeking responses. Indeed, chronic PPX
administration is known to increase Dopamine D2 and D3 recep-
tor mRNA, D3 dopamine receptor protein and D3 dopamine
receptor binding in the striatum and Acb of animals (Maj et al.,
2000; Tokunaga et al., 2012).
In this context, the administration of the D3 preferring ago-
nist before the presentation of the sucrose solution, in addition
to the dopamine release elicited by the consumption of palat-
able food (Bassareo and Di Chiara, 1999), could have interfered
with the consummatory aspect of food presentation. Such hyper-
activation of the dopaminergic system could have positively
modulated approach behavior (such as “searching,” “wanting”)
toward the sucrose solution in rats under chronic PPX treatment.
However, besides the difference in the pattern of Dopamine D3
receptor positive cells between Sh-PPX and L-PPX, no differ-
ence in sucrose tolerance was observed. One possible explanation
could be that increased Dopamine D3 receptor expression is only
a part of a larger change in brain neurochemistry sustaining toler-
ance for sucrose. It is known that the lesion of the dopaminergic
brain region leads to a profound change in brain neurochemistry
and particularly in GABA and glutamate release (Kickler et al.,
2009; Chassain et al., 2010, 2013). Such modifications were not
explored in the present work and could be addressed in further
experiments.
We also noted changes in the expression of anxiety when access
to a sweet solution is removed, whatever the experimental groups
considered. Such an increase of anxiety in animals after removing
access to sucrose has been observed by Hoebel et al. (2007) and
Avena et al. (2008b), pointing to opiate-like withdrawal behaviors
when sucrose is no longer presented. The change in anxiety may
reflect the effect of withdrawal from preferred fluids or drugs that
induce negative or aversive states that potentially lead to a relapse
of drug consumption (Erb, 2010; Pickens et al., 2011). However,
we observed specific changes in anxiety in animals under chronic
PPX treatment. L-PPX and, to a lesser extent, Sh-PPX showed
increased anxiety compared to their respective controls (L and Sh
groups). Such a change in anxiety seems to be linked to dopamine
agonist treatment, since the lesion of dopamine system did not
modify anxiety in the animal model on its own (Carvalho et al.,
2013). The present increase of anxiety in the rats treated could
accounts for the higher tolerance for sucrose. Indeed, although
the animals were more anxious, they could have been more sen-
sitive to the withdrawal effect observed in the 12 h period when
sucrose was not accessible. Anxiety is one of the factors that
contributed to addiction or relapse in humans and rats (Erb,
2010).
Our behavioral results also revealed that neither 1 week of daily
treatment by PPX, nor the VTA lesion had an impact on sponta-
neous locomotor activity and spontaneous alternation in the Y
maze. This result is in agreement with studies showing that lesion
of the VTA has no impact on locomotor activity (Pioli et al., 2008;
Drui et al., 2013; Ouachikh et al., 2013). The absence of modifi-
cation of locomotor activity could be also due to the PPX dose
chosen in the present experiment. We used a dose of 0.1mg/kg
based on the study of Collins et al. (2005), showing that such a
low dose induced preferential activation of the D3 receptor. In
addition, this low dose induced brief hypolocomotion after injec-
tion (30min periods) without inducing hyperlocomotion (Chang
et al., 2011). In the present work, in order to avoid a confounding
effect of PPX on locomotion, we subjected animals to behavioral
tasks at least 2 h after PPX injection. The fact that the animals did
not display disturbed locomotion with lesions or with PPX treat-
ment allowed us to validate our results for the other behavioral
tasks.
To conclude, the present results showed that long-term stim-
ulation of the D3 receptor using PPX induced an increase in
sucrose solution intake as well as in the rate of escalation in
sham animals and lesioned rats, along with an increase of the
expression of the D3 receptor in the ACb. Despite an increase
of D3 receptor expression in Acb compared to sham PPX, no
change of sucrose solution intake was observed in lesioned ani-
mals receiving PPX, thus showing the main role played by PPX in
this behavior compared to the VTA lesion itself.
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